MedTrace Logo

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3501

Last updated 2026-05-18

No results posted yet for this study

Summary

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

Conditions

  • Obesity and Overweight

Interventions

DRUG

MET097

Once-weekly MET097 administered via subcutaneous injection

DRUG

Placebo

Once-weekly placebo administered via subcutaneous injection

Sponsors & Collaborators

  • Metsera, a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-19
Primary Completion
2027-09-21
Completion
2028-04-25
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Bulgaria
  • Canada
  • Czechia
  • Germany
  • Poland
  • Romania
  • Slovakia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07311850 on ClinicalTrials.gov